Meeting the Challenge: Transforming Patient Care in sHTG and FCS With Novel RNA-Based Therapies

CE Information

1.25 contact hours

Completion Time

1 hour, 15 minutes

Available Until

April 20, 2026

Posted By

NP Events

Ready to start this activity?

Already registered? Please log in to see your registration information.

You will be redirected to the association site for Nurse Practitioner Events to complete your registration.

Navigate

Overview

Specialties

Acute Care, Adult, Family, and Gerontological

Subspecialties

Cardiovascular and Hospital Medicine

Clinical Topics

Cardiovascular Disease, Gene Therapy, and Genetic Disease

Target Audience

This activity is intended for cardiology physicians, nurse practitioners, and physician associates who care for patients with sHTG, including FCS.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Dyslipidemia.

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify the pathophysiology of severely elevated triglycerides and the current challenges experienced by patients with sHTG and FCS
Evaluate the latest clinical safety and efficacy data on rapidly emerging therapies for sHTG and FCS
Formulate treatment plans using novel therapies aimed at addressing gaps in the care of patients with sHTG and FCS

Speakers

Christie M. Ballantyne MD

United States of America
JS Abercrombie Chair, Atherosclerosis and Lipoprotein Research
Professor of Medicine and Molecular and Human Genetics
Baylor College of Medicine
Chief, Cardiology and Cardiovascular Research
Director, Center for Cardiometabolic Di

Michael Shapiro DO

Fred M. Parrish Professor of Cardiology and Molecular Medicine
Director, Center for Prevention of Cardiovascular Disease
Section on Cardiovascular Medicine
Wake Forest University School of Medicine
Winston Salem, NC

CE Information

This activity offers 1.25 contact hours to attendees.

Accredited by ANCC.

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Disclosures

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Christie M. Ballantyne, MD: consultant/advisor/speaker: 89bio, Abbott Diagnostics, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Illumina, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostics.

Michael D. Shapiro, DO, MCR, FACC, FAHA: consultant/advisor/speaker: Amgen, Arrowhead, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Tourmaline Bio.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Register For This Activity

OnDemand Course Registration

Select this option to access the activity at no cost

Free

Select

Back to navigate